Article Hero

Robust immune response from AstraZeneca’s COVID-19 drug

1605867821.jpg
Miguel A. Rodriguez
Miguel A. Rodriguez
23 November 2020
AstraZeneca joins Moderna and Pfizer in combating COVID-19

The race for finding a viable COVID-19 vaccine intensified in the past couple of weeks. After Moderna and Pfizer announced that their experimental COVID-19 vaccines have over 90% effectiveness in preventing the infection, another company reported impressive results.

AstraZeneca stated that according to the early-stage trials, its vaccine triggers an immune response among adults. The data collected from 560 volunteers revealed that the adults aged between 18 and 55 and those over 56 had a similar immune response.

“We’re really delighted with the results,” stated Professor Andrew Pollard, Head of Oxford’s vaccine trial team.  The vaccine - ChAdOx1 nCoV-19 showed a response 14 days after the first administrated dose, while antibodies appeared 28 days after the second dose, which is considered a booster.

As stated before, other pharma companies announced their vaccines’ effectiveness. Pfizer, whose vaccine is 95% effective in preventing COVID-19 infection, is said to file for an emergency use application to the FDA later today. Moderna is expected to do the same in the following days.

In pre-market trading, AstraZeneca stock price gained 1.80%.

Read here and here about Moderna and Pfizer’s vaccines!

Sources: cnbc.com

This information/research prepared by Miguel A. Rodriguez does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The research analyst primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views and consequently any person acting on it does so entirely at their own risk.The research provided does not constitute the views of KW Investments Ltd nor is it an invitation to invest with KW Investments Ltd. The research analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.The research analyst in not employed by KW Investments Ltd. You are encouraged to seek advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit that conforms to your specific investment objectives, financial situation, or particular financial needs before making a commitment to invest. The laws of the Republic of Seychelles shall govern any claim relating to or arising from the contents of the information/ research provided. 

Share this article

How did you find this article?

Awful
Ok
Great
Awesome

Read More

Miguel A. Rodriguez
Miguel A. Rodriguez
Financial Writer

Miguel worked for major financial institutions such as Banco Santander, and Banco Central-Hispano. He is a published author of currency trading books.